← Back to Search

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist

Semaglutide + Closed-Loop Therapy for Type 1 Diabetes (SEMA-AP Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
A clinical diagnosis of T1D for at least one year, as per their treating diabetes physician in agreement with the primary investigator's clinical judgment (confirmatory C-peptide and antibodies will not be required)
Agreement to the use of highly effective method of birth control in persons of child-bearing age (if sexually active) and active avoidance of pregnancy during the trial. Child-bearing potential refers to participants of the female sex post-menarche and have not reached menopause or have a disclosed medical condition causing sterility (e.g. hysterectomy). Post-menopausal state refers to the absence of menses for 12 months without any alternative cause.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 weeks
Awards & highlights

SEMA-AP Trial Summary

This trial is testing if semaglutide, a once-weekly injectable medication, can improve glucose control in those with type 1 diabetes when used with a closed-loop insulin system.

Who is the study for?
This trial is for individuals with type 1 diabetes who have been using an insulin pump for at least 3 months and have a glycated hemoglobin (HbA1c) level up to 11%. Participants should not be pregnant, breastfeeding, or planning pregnancy and must agree to use effective birth control. They shouldn't have a history of certain thyroid cancers, pancreatitis, gallbladder disease, severe hypoglycemia recently, or any serious medical condition that could affect participation.Check my eligibility
What is being tested?
The study tests if weekly injections of Semaglutide can improve blood sugar control in people with type 1 diabetes when used alongside a closed-loop insulin system (artificial pancreas). The trial compares the effects of Semaglutide against a placebo over an outpatient therapy period including usual treatment plus four weeks of closed-loop therapy.See study design
What are the potential side effects?
Potential side effects may include digestive issues like nausea or vomiting due to the effect on gastric emptying; low blood sugar levels; possible inflammation of organs such as the pancreas; and allergic reactions. As this drug affects appetite and digestion, changes in eating habits might also occur.

SEMA-AP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Type 1 Diabetes for at least a year.
Select...
I agree to use effective birth control and avoid pregnancy during the trial.
Select...
I agree to use effective birth control and avoid pregnancy during the trial.
Select...
I have been using an insulin pump for at least 3 months.

SEMA-AP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of time of plasma glucose levels spent in target range (semaglutide vs placebo)
Secondary outcome measures
Average scores between interventions based on quality of life questionnaires
Biochemical analyses (exploratory)
Blood pressure and heart rate
+12 more

SEMA-AP Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Semaglutide, Ozempic® (at maximum tolerated dose) + closed-loop insulin systemExperimental Treatment1 Intervention
Semaglutide is a Glucagon-Like Peptide 1 Receptor Agonist. It stimulates GLP1 in the body, which allows for increased satiety, reduced glucagon levels, delayed gastric emptying, and in some, increased insulin secretion. It is a once per week subcutaneous injection.
Group II: Placebo + closed-loop insulin systemActive Control1 Intervention

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
441 Previous Clinical Trials
159,042 Total Patients Enrolled

Media Library

Semaglutide (Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05205928 — Phase 2 & 3
Type 1 Diabetes Research Study Groups: Placebo + closed-loop insulin system, Semaglutide, Ozempic® (at maximum tolerated dose) + closed-loop insulin system
Type 1 Diabetes Clinical Trial 2023: Semaglutide Highlights & Side Effects. Trial Name: NCT05205928 — Phase 2 & 3
Semaglutide (Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05205928 — Phase 2 & 3
Type 1 Diabetes Patient Testimony for trial: Trial Name: NCT05205928 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people are enrolled in this research project?

"Yes, this is an ongoing recruitment effort as indicated by the clinicaltrials.gov listing. This particular trial was posted on 8/2/2022 and updated as recently as 10/3/2022. They are looking for 28 participants at a single site."

Answered by AI

Can patients still join this particular research project?

"That is correct, the information available on clinicaltrials.gov reveals that this trial is still recruiting patients. This study was initially posted on August 2nd, 2020 and has been edited as recently as October 3rd, 2020. The researchers conducting this trial are looking for 28 individuals at a single location."

Answered by AI

Who else is applying?

What site did they apply to?
Research Institute of the McGill University Health Centre
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

I am a type 1 diabetic and love to be a part of pushing the field, and treatment, forward.
PatientReceived 1 prior treatment
Hi, I want like to take part of this trial because the heavy condition of type 1 diabetes is what i live day and night from 7 years and to be part of a clinical trial on diabetes is very concerning for me, the everyday pain and frequent unbalances due to my very active life and addiction to sugar make me want to fight, learn more, understand more and help.
PatientReceived 2+ prior treatments

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. Research Institute of the McGill University Health Centre: < 48 hours
Average response time
  • < 2 Days
~8 spots leftby Dec 2024